Lonnel Coats, Lexicon Pharmaceuticals CEO
July 13, 2022 01:14 PM EDTUpdated 03:57 PM
FDA+

FDA again spells out safe­ty con­cerns with oral type 1 di­a­betes drug while deny­ing Lex­i­con's at­tempt to over­turn a CRL

Zachary Brennan

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times